The upcoming report from Edgewell Personal Care (EPC) is expected to reveal quarterly earnings of $0.90 per share, indicating an increase of 2.3% compared to the year-ago period. Analysts forecast revenues of $590.67 million, representing a decrease of 1.5% year over year. The consensus EPS estimate for the quarter has undergone a downward revision of 0.5% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective. Bearing this in mind, let's now explore the average estimates of specific Edgewell Personal metrics that are commonly monitored and projected by Wall Street analysts. According to the collective judgment of analysts, 'Net Sales- Feminine Care' should come in at $66.82 million. The estimate indicates a year-over-year change of -5.2%. The consensus among analysts is that 'Net Sales- Wet Shave' will reach $287.81 million. The estimate indicates a change of -1.8% from the prior-year quarter. The combined assessment of analysts suggests that 'Net Sales- Sun and Skin Care' will likely reach $236.08 million. The estimate suggests a change of +0.1% year over year. View all Key Company Metrics for Edgewell Personal here>>> Over the past month, Edgewell Personal shares have recorded returns of +9.5% versus the Zacks S&P 500 composite's +11.5% change. Based on its Zacks Rank #3 (Hold), EPC will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Edgewell Personal Care Company (EPC):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
What Analyst Projections for Key Metrics Reveal About Edgewell Personal (EPC) Q2 Earnings
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...